ArticleNature biomedical engineering2023
Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting.
Article in Nature biomedical engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Mechanistic insights into cellular deformation enable enhanced extensional-flow cytometry for label-free classification and sorting.Microsystems & nanoengineering · 2026Article
- Engineering Organ-on-a-Chip Systems for Cancer Immunotherapy: Strategies and Assay Integration.Bioengineering (Basel, Switzerland) · 2026Review
- Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma.Immuno-oncology technology · 2026Article
- Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer.Nature communications · 2026Article
- Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges.Cancer immunology, immunotherapy : CII · 2026Review
- Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.Journal for immunotherapy of cancer · 2026Review
- Microsystem technologies for accelerating the discovery and translation of immunotherapies.Nature reviews. Drug discovery · 2026Review
- Magnetically Sculpted Microfluidics for Continuous-Flow Fractionation of Cell Populations by EpCAM Expression Level.Micromachines · 2025Article
- Advances in machine learning-enhanced microfluidic cell sorting.Science advances · 2025Review
- Facts and Hopes for Neoantigen-Enriched TIL.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Single-cell RNA-sequencing of circulating tumour cells: A practical guide to workflow and translational applications.Cancer metastasis reviews · 2025Review
- Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review).International journal of oncology · 2025Review
- Polymerised superparamagnetic antigen presenting cell lymphocyte capture for enriching tumour reactive T-cells and neoantigen identification.Nature communications · 2025Article
- Microfluidic technologies for enhancing the potency, predictability and affordability of adoptive cell therapies.Nature biomedical engineering · 2025Review
- Mesothelioma cell heterogeneity identified by single cell RNA sequencing.Scientific reports · 2025Article
- Rapid and comprehensive detection of viral antibodies and nucleic acids via an acoustofluidic integrated molecular diagnostics chip: AIMDx.Science advances · 2025Article
- Swarm Autonomy: From Agent Functionalization to Machine Intelligence.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Viscoelastic synthetic antigen-presenting cells for augmenting the potency of cancer therapies.Nature biomedical engineering · 2024Article
- A Capillary-Force-Driven, Single-Cell Transfer Method for Studying Rare Cells.Bioengineering (Basel, Switzerland) · 2024Article
- Phenotypic targeting using magnetic nanoparticles for rapid characterization of cellular proliferation regulators.Science advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
The clinical use of tumour-infiltrating lymphocytes for the treatment of solid tumours is hindered by the need to obtain large and fresh tumour fractions, which is often not feasible in patients with unresectable tumours or recurrent metastases. Here we show that circulating tumour-reactive lymphocytes (cTRLs) can be isolated from peripheral blood at high yield and purity via microfluidic immunomagnetic cell sorting, allowing for comprehensive downstream analyses of these rare cells. We observed that CD103 is strongly expressed by the isolated cTRLs, and that in mice with subcutaneous tumours, tumour-infiltrating lymphocytes isolated from the tumours and rapidly expanded CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.